SAB Biotherapeutics to Present at the BIO CEO & Investor Conference [Yahoo! Finance]
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: Yahoo! Finance
biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company's Chairman and CEO, will present an overview of the Company at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 3:15 PM EST. During the presentation, Mr. Reich will highlight the latest developments from the Company's lead clinical program, SAB-142, a novel biologic being developed for delaying onset and progression of Type 1 diabetes in adults and children, as well as partnership and investment opportunities. Mr. Reich's presentation is entitled, “Fully Human Anti Thymocyte Biologic Developed to Delay Onset or Progression of Type 1 Diabetes.” The conference is one of the industry's largest gatherings for institutional investors, industry analysts, and senior executives in the biotechnology industry. About SAB Biotherapeutics,
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.MarketBeat
- SAB Biotherapeutics Provides SAB-142 Trial Update [Yahoo! Finance]Yahoo! Finance
- SAB Biotherapeutics Provides SAB-142 Trial UpdateGlobeNewswire
- SAB Biotherapeutics to Present at INNODIA Annual Meeting [Yahoo! Finance]Yahoo! Finance
SABS
Earnings
- 8/21/23 - Beat
SABS
Sec Filings
- 4/15/24 - Form 8-K
- 3/29/24 - Form 8-K
- 3/29/24 - Form 10-K
- SABS's page on the SEC website